Research

Hormonal

In patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, achieving MASH resolution and fibrosis improvement is significantly associated with greater reductions in body weight, improved glycemic control (HbA1c), and normalization of liver fat.

If you have MASH with fibrosis, achieving significant weight loss, better blood sugar control, and normalizing liver fat are key steps toward resolving the disease. Tirzepatide, taken once weekly and titrated up from 2.5mg to 5-15mg over several months, has been shown to facilitate these metabolic changes, which in turn drive histological improvement in the liver.

GoodSupportsHIGH confidence
In the overall study population, responders for both MASH resolution and fibrosis improvement had greater reductions in weight, HbA1c, and normalization of liver fat compared with nonresponders.
Cyrielle Caussy et al. · Diabetes Care · 2025

Why this rating

Post hoc analysis of a phase 2 randomized controlled trial (SYNERGY-NASH) with a substantial sample size (n=154 analyzed), though exploratory.

Source

Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction– Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide

Cyrielle Caussy et al. · Diabetes Care · 2025

DOI 10.2337/dc25-1306

rct · n=190Cited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →